Primary liver cancer Liver cirrhosis Liver fibrosis Chronic hepatitis B Chronic hepatitis C Alcoholic liver disease Non-alcoholic steatohepatitis Autoimmune hepatitis
Conditions
Interventions
Index test:GADA Hepatocellular Carcinoma Risk Assessment Model
Gold Standard:The clinical diagnostic criteria for patients with primary liver cancer refer to the "Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition)".
Sponsors
Shandong Provincial Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Liver cancer group (experimental group) : 1. Age 18 years old and above, gender not limited; 2. Patients clinically diagnosed with HCC and confirmed by radiology or liver biopsy; 3. The staging information of liver cancer is clear. The staging of liver cancer was scored using the Chinese Liver Cancer Staging Protocol (CNLC). Stage I is the early stage, stage II is the middle stage, stage III is the advanced stage, and stage IV is the terminal stage. Chronic liver disease (control group) : 1. Age 18 years old and above, gender not limited; 2. Clinically diagnosed as chronic hepatitis B, chronic hepatitis C, alcoholic hepatitis, non-alcoholic steatohepatitis, autoimmune hepatitis, liver fibrosis, liver cirrhosis, etc. 3. For some patients suspected of having liver cancer, it is necessary to confirm the absence of HCC through imaging results within 12 months before enrollment.
Exclusion criteria
Exclusion criteria: 1.Subjects who meet any of the following conditions will not be eligible to participate in this study: 1. Presenting as an uncertain liver mass or a liver mass that meets the radiological criteria of HCC; 2. Any other form of cancer (excluding melanoma skin cancer); 3. Recurrent HCC, having undergone or currently undergoing HCC treatment; 4. The glomerular filtration rate of the patient was less than 60 mL/min/1.73 m2; 5. Currently undergoing anti-vitamin K coagulation therapy (such as warfarin, phenylpropofol or asenocortol); 6. Those with a history of transplantation of major functional organs; 7. The subject has a clinical and laboratory-proven history of pancreatitis, or has presented clinical or laboratory manifestations related to the current pancreatitis; 8. Other circumstances where the researcher deems it unsuitable for inclusion in the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alpha-fetoprotein(AFP)?Protein Induced by Vitamin K Absence or Antagonist-II(PIVKA-II)?Golgi Protein 73(GP73);Accuracy;Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactZhuangXuewei
Shandong Provincial Third Hospital
Outcome results
None listed